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Context: Papillary thyroid microcarcinoma (PTMC) is an indolent neoplasia, often asymptomatic
anddiscovered incidentally. SomePTMCs, however, exhibit amoreaggressivebehavior, frequently
recur, and can even cause cancer-related death.
Objective: The aim of this study was to evaluate the prevalence of PTMCs and the associated risk
factors at presentation in 2 thyroid cancer registries from areas with different genetic and envi-
ronmental characteristics.
Design and Patients: We conducted a retrospective, observational study of all incident cases of
PTMCs recorded over a 5-year period in the Sicilian Regional Registry for Thyroid Cancer (SRRTC)
and in the Surveillance Epidemiology and End Results (SEER) US registry.
Setting: The study took place at an academic hospital.
Results: The incidence of PTMCs was much higher in Sicily (1777 PTMC diagnosed in 2002–2006;
age-standardized incidence rate for the world population [ASRw]  5.8 per 100 000) than in the
United States (14 423 PTMC in the period 2004–2008; ASRw 2.9 per 100 000). Within the SRRTC,
a significantly higher incidence was observed in the volcanic area (ASRw  10.4 vs 4.6 in the rest
of Sicily). In Sicily, the female to male ratio was higher, and PTMC patients were younger. In both
registries, a significant inverse correlation was observed between age and tumor size. Young
patients (45 y) exhibited a higher frequency of nodal metastases.
Conclusions: PTMC incidence is twice as high in Sicily comparedwith the United States, andwithin
Sicily, the incidence is twice as high in the volcanic area. In young patients, PTMCs are larger at
presentation and exhibit more risk factors. In both registries, more than 35% of PTMCs exhibited
2 or more risk factors, suggesting that they may require surgery and follow-up similar to that of
larger carcinomas. (J Clin Endocrinol Metab 98: 1427–1434, 2013)
Thyroid microcarcinomas, ie, thyroid cancers smallerthan 1 cm in diameter, have become a public health
issue due to the continuous worldwide increase of thyroid
cancer incidence, with microcarcinomas representing
nearly 50% of all thyroid cancers. Microcarcinoma is a
definitionbasedon size,with no informationon the tumor
biology. Most thyroid microcarcinomas exhibit indolent
behavior and require neither aggressive treatment nor in-
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tensive follow-up, as indicated by recent guidelines (1, 2).
For these tumors, the risk of overdiagnosis (ie, the iden-
tification of small tumors that will never cause health
problems) is a strong possibility. Overdiagnosis carries
the risk of overtreatment, with a consequent burden of
potential complications, patient distress, and economic
costs (3).
However, at an early stage, also aggressive tumors will
appear asmicrocarcinomas.Whenundertreated, thesemi-
crocarcinomas can progress with extrathyroid extension,
lymph node invasion, and distant metastases. Eventually,
these cancers exhibit an increased recurrence rate as well
as the potential for cancer-related death (4, 5).
It is therefore important to identify which microcarci-
nomas are likely to progress and recur when treated with
a more conservative clinical approach. A series of clinical
parameters, including characteristics of both the micro-
carcinoma (size, multifocality, histological variants, vas-
cular or capsular invasion, lymph node metastases, and
rare distant metastases) and the host (age, gender, previ-
ous irradiation, and ethnicity), have been proposed for
stratifying the risk level and defining a risk-adapted algo-
rithm for a rational approach to thyroid microcarcinoma
treatment and follow-up (6, 7).
To verify the prevalence of the above-mentioned risk
factors and to determine whether these risk factors are
similarly distributed and associated in different environ-
mental and ethnic settings, we analyzed 2 thyroid cancer
registries from geographic areas that are different in terms
of ethnicity, environment, and lifestyle. The large micro-
carcinoma series of the Sicilian Regional Registry of Thy-
roid Cancer (SRRTC, Sicily, Italy) and that of the Surveil-
lance Epidemiology and End Results (SEER, United
States) were analyzed for a similar 5-year period. Because
of the heterogeneous distribution of thyroid cancer inci-
dence in Sicily, with a doubled incidence in the volcanic
area of Catania (8), SRRTC data were analyzed bothwith
and without cases from the province of Catania.
Patients and Methods
All of the papillary thyroid microcarcinomas (PTMCs;10mm
indiameter) from the SRRTCwere retrospectively selected in the
5-year period 2002–2006. Case recruitment procedures for the
SRRTC have been described previously (8) and are based on
pathology diagnoses. Papillary microcarcinomas represented
98.0%(1777of1814)of allmicrocarcinomasdiagnosed inSicily
in the study period.
Data from the National Cancer Institute’s SEER 18 registry
were analyzed after selecting all new cases of PTMCs in the
5-year period 2004–2008 using the International Classification
of Disease for Oncology (ICD-O-3) codes 8050, 8052, 8260,
8340–8344, and 8450. Papillary microcarcinomas represented
98.3% (14 423 of 14 671) of all microcarcinomas registered in
the SEER in the study period.
The following parameters were analyzed because they were
available in both registries: histotype, age at diagnosis (45 vs
45 y), gender, extent of surgery (total or near-total thyroidec-
tomy vs hemithyroidectomy), tumor size (6 mm vs 6 mm
maximum diameter), extrathyroid extension (including both
minimal and large extrathyroid invasion), multifocality (includ-
ing both uni- and bilateral cancer foci), and TNM category clas-
sified according to the 7th edition of the American Joint Com-
mittee on Cancer, Cancer Staging Manual (9).
Six patients from the SRRTC series who were missing the
information regarding age at diagnosis were excluded from the
study.
Because a much higher incidence of thyroid cancer is present
in the volcanic area of Sicily (8), the Sicilian cohort of microcar-
cinoma patients was subdivided intomicrocarcinomas from res-
idents in the province of Catania (volcanic area, approximately
1 million inhabitants; n  675 PTMCs) and residents from the
rest of Sicily (approximately 4 million inhabitants; n  1102
PTMCs).
Statistical analysis
Quantitative data are shown as the mean  SD, whereas
numbers and percentages are provided for qualitative data. Per-
centages were compared using the 2 test, and the t test was used
for continuous variables. Pearson’s correlation coefficient was
calculated to investigate the relationship between age at diag-
nosis and tumor size by plotting the 5-year age intervals and the
mean tumor diameter at each interval. Age-standardized inci-
dence rate for the world population (ASRw) and the 95% con-
fidence intervals (CIs) were calculated for both male and female
patients (10).Data are expressed as the number of newdiagnoses
per 100 000 persons per year. All tests were 2-sided, and a P
value 0.05 was considered statistically significant. Data from
the SEER refer to the last release (April 2012, based on the No-
vember 2011 submission) and were obtained through the
SEER*Stat software version 7.0.9. Statistical analyses were per-




In the 5-year period between 2002 and 2006, 1777
patients with PTMCs were diagnosed in Sicily, a Medi-
terranean islandwith approximately 5million inhabitants
(n  5 003 262 residents in 2004 according to the Ital-
ian Institute for Statistics; http://demo.istat.it/pop2004/
index.html). PTMCs represent 51.7% of all thyroid can-
cers diagnosed in Sicily during that period, with an ASRw
of5.8per105 inhabitants (95%CI5.2–6.4), 9.5per105
in females and 1.8 per 105 in males (Table 1).
The clinical and histopathological features of the PT-
MCs are presented in Table 2.
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Age and gender
The mean age at diagnosis was 49.4  13.2 years.
The female-to-male ratio was 5.4:1.0. This ratio was
significantly higher in patients younger than 60 years
(5.8:1.0) than it was in older patients (4.1:1.0; P .03).
PTMCs were diagnosed before the age 45 years in 693
cases (39.0%), with a similar proportion in the 2 gen-
ders (Table 2).
Tumor size
The mean PTMC size was 5.5  3.0 mm. There were
679 (38.2%) tumors larger than 6 mm in maximum di-
ameter (7–10 mm). The prevalence of larger (6 mm)
PTMCs was similar in males (101 of 279; 36.2%) and in
females (578 of 1498; 38.6%; P  .46).
The average tumor size was significantly higher in
younger patients (up to 45 y old, corresponding to 39%of
the studied cohort) than in older subjects (5.9  3.0 vs
5.3  2.9 mm, respectively; P  .0001). A significant in-
verse relationship was observed between tumor size and
age at diagnosis (r  0.63; P  .011) (Figure 1A).
Extent of primary tumor
Lymph nodes were removed in 456 of 1777 (25.7%)
patients on the basis of either primary tumor characteris-
tics (multifocality, capsule invasion and/or extrathyroid
extension) or the presence of suspicious lymph nodes dur-
ing a presurgery ultrasound (US) cervical scan. These cri-
teria, however, were not used in all surgeries and were
rarely used in incidental cases. Lymph node metastases
Table 2. Clinical and Histopathological Features of Both SRRTC and SEER PTMC Patients
Parameters at Diagnosis SRRTC (n  1777) SEER (n  14 423) P Value
Gender, F/M [ratio] 1498/279 [5.4] 11 743/2680 [4.4] .003
Age (mean  SD), y 49.4  13.2 50.6  13.9 .001
Age  45 yr 693 (39.0) 5287 (38.3) .04
F 589 (39.3) 4586 (39.1) .74
M 104 (37.3) 701 (26.2) .0001
Tumor size (mean  SD), mm 5.5  3.0 5.4  3.0 .06
Tumor  6 mm 679 (38.2) 5524 (38.3) .96
F 578 (38.6) 4466 (38.0) .69
M 101 (36.2) 1058 (39.5) .30
Lymph nodes (N1) 125 (27.4)a 1628 (28.9)a .52
F 96 (25.4)b 1092 (23.8)b .49
M 29 (37.2) 536 (50.8) .03
Extrathyroid extension 134 (7.5) 900 (6.2) .04
F 113 (7.5) 678 (5.8) .008
M 21 (7.5) 222 (8.3) .73
Multifocality 462 (26.0) 4834 (33.5) .0001
F 382 (25.5) 3876 (33.0) .0001
M 80 (28.7) 958 (35.7) .01
Abbreviations: F, female; M, male. Data are expressed as number (percentage) unless otherwise specified.
a Percentage calculated in the 456 patients of the SRRTC and in the 5637 of the SEER in whom lymph nodes were removed.
b P value  .04 and .0001 with respect to males of SRRTC and SEER, respectively.
Table 1. ASRw for All Thyroid Cancers and Papillary Microcarcinomas According to Residence
All Sicily Catania Province Sicily Without Catania SEER
Total thyroid cancers
Both genders 11.0 (10.2–11.8) 18.4 (16.1–20.8) 8.8 (8.0–9.6)a 8.9 (8.8–9.0)c
F 17.4 (15.9–18.9) 29.5 (25.4–33.6) 13.9 (12.4–15.4)a 13.4 (13.3–13.6)c
M 4.2 (3.5–4.9) 6.5 (4.5–8.5) 3.4 (2.7–4.1)a 4.3 (4.2–4.4)d
Papillary microcarcinomas
Both genders 5.8 (5.2–6.4) 10.4 (8.6–12.2) 4.6 (4.0–5.2)a 2.9 (2.8–3.0)c
F 9.5 (8.4–10.6) 17.0 (13.8–20.2) 7.5 (6.4–8.6)a 4.6 (4.5–4.6)c
M 1.8 (1.3–2.3) 3.3 (1.9–4.7) 1.5 (1.0–2.0)b 1.1 (1.0–1.2)c
Abbreviations: F, female; M, male. Data are expressed as ASRw (95% CI).
a P  .01 vs Catania province cohort.
b P  .05 vs Catania province cohort.
c P  .01 vs all Sicily cohort.
d Not significant vs All Sicily cohort.
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were observed in 125 patients (27.4% of subjects under-
went lymph node excision). Positive lymph nodes were
more frequent in male than in female patients (37.2 vs
25.4%; P .04) (Table 2) and in larger PTMCs (6mm)
(32.5 vs 21.6% in smaller tumors; P  .011). PTMCs in
young patients (45 y), after adjusting for tumor size, had
a higher risk of nodal metastases than did tumors in older
patients (odds ratio 2.4; 95%CI 1.5–3.7;P .0001).
Extrathyroid extension was observed in 134 patients
(7.5%), with no significant difference between genders
(Table 2). Extrathyroid extension was more frequent in
larger (6 mm) PTMCs (13.5 vs 3.8% in 1- to 6-mm
PTMCs; P .0001). Lymph nodes were excised in 402 of
1643 (24.5%) T1 PTMCs and in 54 of 134 (40.3%) T3
PTMCs. Lymphnode positivitywas observed in 23.9%of
T1 patients and in 53.7% of T3 patients.
Total or near-total thyroidectomy was performed in
1642 (92.4%)patients, andonly135 (7.6%)patientswere
treated with hemithyroidectomy. The availability of all
thyroid tissue for pathological examination in over 90%
of cases made possible an accurate evaluation of multifo-
cality.Multifocalitywas observed in 462of 1777 (26.0%)
patients, with a slightly higher prevalence, not statistically
significant, in males (28.7 vs 25.5%; P  .27). Lymph
node involvement was much higher in multifocal than in
nonmultifocal microcarcinomas (40.7 vs 19.7%, respec-
tively;P .0001).Moreover,multifocality occurredmore
frequently in both larger (6 mm) and extrathyroidal
PTMC (31.7 and 53.0%, respectively) with respect to
smaller (6 mm) and intrathyroidal PTMCs (22.5 and
23.8%, respectively; P  .0001 for both differences).
The volcanic area
PTMC incidence was much higher in the volcanic area
of Catania (ASRw  10.4 per 105; 95% CI  8.6–12.2)
than in the rest of Sicily (ASRw 4.6 per 105 inhabitants;
95% CI  4.0–5.2) (Table 1). When comparing PTMCs
occurring in residents of the volcanic areaofCatania to the
rest of Sicily, a higher percentage (P .045) of multifocal
PTMCs was present in the volcanic area (Table 3). No
significant difference was observed for the other param-
eters, although microcarcinomas in the volcanic area had
a tendency to be larger and more frequently exhibited
nodal involvement and extrathyroid extension (Table 3).
Comparison between Sicilian and SEER thyroid
microcarcinoma patients
In the 5-year period between 2004 and 2008, 14 423
PTMCs were recorded in the SEER 18 registry. The inci-
dence rate (ASRw)was 2.9 per 105 inhabitants (95%CI
2.8–3.0), which is significantly lower (P  .01) than the
rate in Sicily, even after excluding the volcanic area (Table
Table 3. Clinical and Histopathological Features of
PTMCs in Patients Living in the Province of Catania or in





Age (mean  SD), y 49.6  13.1 49.3  13.1 .62
Female/male ratio 5.6 5.3 .74
Tumor size (mean 
SD), mm
5.6  3.0 5.5  2.9 .40
6 mm (%) 39.4 37.5 .42




Multifocal (%) 28.7 24.3 .045
a Percentage of N1 cancers among patients who underwent lymph
node excision (n  183 in Catania; n  273 in the rest of Sicily).
Figure 1. Relationship between microcarcinoma size and patient age
at diagnosis.
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1). The different incidence between the 2 registries was
mainly due to the higher incidence in Sicily of PTMC in
patients younger than 60 years. The clinical and histo-
pathological features at diagnosis are summarized in
Table 2.
Age and gender
The mean age at diagnosis was significantly higher in
the SEERcohort.This agedifferencewasmainlydue to the
male gender: male patients 45 years represented 37.3%
of the PTMC cases in Sicily relative to 26.2% in the US
cases (P  .0001). No difference between SRRTC and
SEER was observed in the percentage of young (45 y)
female patients with PTMC (Table 2).
The female to male ratio in the United States (4.4:1.0)
was significantly lower than in Sicily (P  .003). As in
Sicily, however, the female prevalence was higher in pa-
tients younger than 60 years (5.2:1.0) compared with
older patients (2.8:1.0) (P  .0001).
Tumor size
The average PTMC size was similar between the SEER
and SRRTC cohorts (Table 2). The percentage of PTMCs
larger than 6 mm (38.3%) was similar to that of Sicily,
with no difference between the 2 genders (P  .17).
As in Sicily, the mean tumor diameter was greater in
youngpatients (45y) (5.73.0 vs 5.23.0mminolder
patients;P .0001). In addition, thePearson’s correlation
analysis confirmed the inverse relationshipbetween tumor
diameter and age at diagnosis in the SEER series (r 
0.82; P  .0001; Figure 1B). Again, the average tumor
diameter was significantly higher in both males and fe-
males younger than 60 years (males, 5.6  3.0 mm; fe-
males, 5.5  3.0 mm) compared with older patients
(males, 5.1 3.0 mm; females, 5.0 3.0 mm; P .0001
with respect to younger patients of the same gender).
Extent of primary tumor
Lymph node involvement was observed in 1628 of
14 423 (11.3%) patients. This percentage was calculated
on the assumption that all T1 PTMCs in which node ex-
cision was not performed were node negative. The calcu-
lated percentage of involved lymph nodes may be biased
by different selection criteria because the surgical ap-
proach to the evaluation of lymph node metastases was
heterogeneous, and different criteria were used both be-
tween and within the 2 areas studied. However, when the
percentage of cervical node positivity was calculated
among the number of cases in which lymph nodes were
excised, very similar percentages were observed in the
SEER and SRRTC cohorts (Table 2).
As in Sicily, positive lymph nodes in the SEER cohort
were more frequent in male than in female patients (50.8
vs 23.8%, respectively; P  .0001) and in larger PTMCs
(34.9 vs 23.6% in PTMCs smaller than 7mm;P .0001).
After adjusting for tumor size, PTMCs in young patients
(45 y) exhibited a higher risk of nodal metastases than
didPTMCs inolder patients (odds ratio1.26; 95%CI
1.12–1.42; P  .0001).
Extrathyroid extension was significantly less frequent
in US patients than in Sicilian patients (6.2 vs 7.5%, re-
spectively; P  .04). Extrathyroid extension was more
frequent amongmale patients than among female patients
(8.3 vs 5.8%; P  .0001) (Table 1) and, as in Sicily, in
larger PTMCs (11.3 vs 3.2% in 1- to 6-mm microcarci-
nomas; P  .0001). Lymph node involvement was more
frequent in T3 tumors (63.5%) relative to T1 tumors
(24.0%). The percentage of T1 cancers with lymph node
involvement in the SEER cohort was similar to that ob-
served in Sicily, but the percentage of T3 tumors with
lymph node involvement was higher than in Sicily.
Multifocality was present in 4834 (33.5%) patients, a
significantly higher percentage than in Sicily. Lymph node
involvement, as in Sicily, was much higher in multifocal
PTMCs (37.4% of patients with excised cervical nodes)
than in PTMCs without multifocality (21.9%). Multifo-
cality was more frequently observed in both larger (6
mm)and extrathyroidal PTMCs (42.0 and55.3%, respec-
tively)with respect to smaller (6mm) and intrathyroidal
PTMCs (28.9 and32.6%, respectively;P .0001 for both
differences).
The percentage of PTMC patients having 2 or more
than 2 risk factors was higher in the SEER cohort (42.7 vs
37.8% in Sicily; Table 4), despite the lower PTMC inci-
dence in the United States with respect to Sicily.
Discussion
Curative intent is the advisable aim for cancer patients,
even when the cancer has indolent progression, because
malignant evolution can change with time. However, PT-
MCs have recently been considered a disease requiring in
Table 4. PTMC Stratification on the Basis of the







(n  14 423)
P
Value
None 438 (24.7) 3181 (22.0) .014
1 667 (37.5) 5086 (35.3) .06
2 405 (22.8) 3652 (25.3) .02
3 or more 267 (15.0) 2504 (17.4) .015
Data are expressed as number (percentage).
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most casesminimal or no intervention (11). Based on their
frequent incidental discovery (12–14) and the high prev-
alence of occult PTMCs at autopsy (15), it has even been
suggested that PTMCs represent a normal phenomenon
and not cancer (16). It is well recognized, however, that a
certain proportion of PTMCs have an unfavorable out-
come that includes not only cancer-related death (very
low, approximately 0.5%) (17, 18) but also recurrent dis-
ease, with follow-up costs and the burden of worry and
distress for patients and their families. Because PTMCs do
not represent a homogeneous entity, risk-adapted man-
agement is themost rational approach to these tumors. To
stratify PTMCs according to the risk for progression
and/or recurrence, anumberof risk factorshavebeen iden-
tified (7, 19).
A recent study based on the SEER cohort analysis in-
dicates that 2 or more than 2 risk factors at presentation
should prompt more aggressive treatment of PTMCs to
prevent cancer-related mortality (7). Our study follows
similar criteria, but the risk factors analyzed are partially
different from those considered by Yu et al (7), who also
analyzed the impact of ethnicity and the presence of dis-
tant metastases, 2 parameters that are not included in our
study because the Sicilian population is ethnically homo-
geneous and distant metastases in PTMC are very rare
(only 91 of 18 445 or 0.5% in the series of Yu et al) and
are not recorded in the SRRTC. In our analysis, however,
we included the evaluation of 2 additional risk factors
(tumor size and multifocality) that may be relevant when
stratifying PTMCs for the risk of recurrence. Our study
indicates that, using the 6 above-mentioned risk factors at
presentation as surrogate indicators of outcome, in both
registries at least 1 of 3 PTMCs requires extensive surgical
treatment (total or subtotal thyroidectomy with cervical
node excision when appropriate) to avoid or reduce the
risk of recurrence. In some cases, when many risk factors
are present, radioiodine treatment may also be advisable.
The percentage of PTMC patients having 2 or more risk
factors is higher in the SEER cohort, despite a lower
PTMC incidence with respect to the SRRTC cohort.
A novel finding of the present analysis is that young age
(45 y) is a negative factor in PTMCpatients because it is
more frequently associatedwith other negative prognostic
factors than is older age. American Thyroid Association
(ATA) guidelines (Ref. 1, Location key B8) suggest near-
total or total thyroidectomy for older patients (45 y)
with a 1-cm thyroid nodule suspected formalignancy at
cytology. Because both the SRRTC and the SEER cohorts
indicate that young patients, on average, have larger
PTMCs, with more frequent extrathyroid extension and
lymph node metastases even after correcting for tumor
size, we believe that extensive thyroid surgery should also
be recommended for young patients. Microcarcinomas,
therefore, may have a different behavior than macrocar-
cinomas thatmore frequently exhibit adverse outcomes in
patients older than 45 years (20, 21) because risk factors
at presentation, predictive of a higher recurrence rate, are
more frequent in PTMCs occurring at a young age.
Microcarcinoma size is a well-recognized risk factor
frequently associated with all other negative prognostic
factors, including lymph node metastases, extrathyroid
extension, and multifocality. Tumor size, therefore, fol-
lows a continuous negative trend, with smaller PTMCs
exhibiting better prognosis than larger (6 mm) PTMCs,
and carcinomas  10 mm having a better outcome than
10- to 15-mmand10- to 20-mmcancers (5, 22). Small size
alone (6mm), however, is not a guarantee of low risk. In
both registries, a significant number of PTMCs  6 mm
had 2 or more associated risk factors (17.1% in SRRTC
and 21.2% in SEER), a feature predicting unfavorable
outcomes (7).
Lymph node involvement in both studied cohorts was
lower than that reported in most series of microcarcino-
mas from a single center (23). This result is the probable
consequence of the registry recruitment characteristics
that aggregate data obtained using varied surgical ap-
proaches to metastatic lymph node detection. Most sur-
geons, in fact, do not proceed to central compartment
lymph node excision after an incidental microcarcinoma
discovery or after a PTMC is diagnosed before surgery
because the microcarcinoma risk level is not assessed.
Among patients with T1 PTMC who underwent lymph
node dissection, more than 20% exhibited metastatic
lymph nodes. The assumption that T1 microcarcinomas,
when not explored at surgery, do not have lymph node
involvement likely results in the underestimation of the
true rate of local PTMC metastases in the SEER.
When comparing data from the 2 registries, the higher
PTMCincidence in Sicily is characterizedbya younger age
at presentation andmore frequent extrathyroid extension
(Table 2). The percentage of lymph node involvement is
difficult to judge because of the heterogeneous and poorly
defined selection criteria for lymph node excision. Multi-
focality, however, is significantly more frequent in the
United States. This findingmay be dependent on themore
zealous search for cancer foci by the US pathologists but
could also depend on genetic cancer characteristics or in-
fluences of environmental factors. According to the ATA
guidelines (Ref. 1, recommendation 32), multifocality
should no longer be considered a risk factor requiring ra-
dioiodine as adjuvant therapy when all cancer foci are
smaller than 10 mm. Whether prophylactic lymph node
excision is appropriate for multifocal PTMCs is not de-
fined. In accordance with recent observations indicating
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that multifocality is associated with more frequent recur-
rence (4, 24, 25), our data from the analysis of both reg-
istries also confirm that multifocality is frequently asso-
ciatedwith larger cancer size, lymph nodemetastases, and
extrathyroid invasion.Multifocality, therefore, should be
considered an important risk factor when evaluating the
overall risk stratification of PTMCs, and postsurgical ra-
dioiodine ablation should be considered for patients hav-
ing a multifocal microcarcinoma with a tumor maximum
diameter  6 mm, young age (45 y), and male gender,
even when no data are available on lymph node status.
Our study has an important limitation because it does
not include follow-up analyses, and risk factors at presen-
tation are only surrogate indicators of the real outcome of
the cancer. The evaluation of these risk factors at presen-
tation by surgeons and pathologists has a significant sub-
jective component and can be influenced by their expertise
and accuracy. Clinicians that assist thyroid cancer pa-
tients, however, have to rest upon these factors to decide
treatment and follow-up intensity.We thought itwouldbe
interesting, therefore, to compare large series of micro-
carcinomas in 2 independent areas and evaluate similar-
ities and differences. The large number of observations
(over 16 000 PTMCs), in fact, may compensate for vari-
ability of individual/regional observations for better de-
fining the prevalence of PTMCs that are at risk of pro-
gression and recurrence. On the other hand, the feasibility
of prospective studies on microcarcinoma outcome is low
because PTMCs would require decades of follow-up due
to the indolent behavior of these tumors. The future mo-
lecular characterization of PTMCbiology (26, 27) should
overcome theuncertainty regarding the riskofprogression
and, consequently, will better indicate the most appropri-
ate treatment for PTMCs in terms of cost/benefit. At pres-
ent, based on the clinical characteristics at presentation
(concordant in 2 large registries), PTMCrisk stratification
should suggest total thyroidectomy in at least 1 of 3
PTMCs, specifically in the case of larger microcarcinoma
size and in young, male patients. Moreover, a careful as-
sessmentof cervical lymphnode involvement is required in
these patients when the cancer exhibits extrathyroid ex-
tension and/or is multifocal.
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